TBX2 Drives Neuroendocrine Prostate Cancer through Exosome-Mediated Repression of miR-200c-3p

被引:10
|
作者
Patel, Girijesh Kumar [1 ]
Dutta, Sayanika [1 ]
Syed, Mosharaf Mahmud [1 ]
Ramachandran, Sabarish [1 ]
Sharma, Monica [2 ]
Rajamanickam, Venkatesh [3 ]
Ganapathy, Vadivel [1 ]
DeGraff, David J. J. [4 ]
Pruitt, Kevin [2 ]
Tripathi, Manisha [1 ,5 ]
Nandana, Srinivas [1 ,5 ]
机构
[1] Texas Tech Univ, Hlth Sci Ctr, Dept Cell Biol & Biochem, Lubbock, TX 79430 USA
[2] Texas Tech Univ, Hlth Sci Ctr, Dept Immunol & Mol Microbiol, Lubbock, TX 79430 USA
[3] Providence Canc Inst, Earle A Chiles Res Inst, Portland, OR 97213 USA
[4] Penn State Univ, Coll Med, Dept Pathol & Lab Med, Hershey, PA 17033 USA
[5] Texas Tech Univ, Hlth Sci Ctr, Dept Urol, Lubbock, TX 79430 USA
关键词
exosomes; N-MYC; SOX2; TBX2; treatment-induced neuroendocrine prostate cancer; miR-200c-3p; TRANSCRIPTION FACTOR TBX2; PROMOTES; SUPPRESSION; METASTASIS; RESISTANCE; MICRORNAS; MECHANISM; GENOMICS; GROWTH; CELLS;
D O I
10.3390/cancers13195020
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
An estimated similar to 25-30% of patients with advanced prostate cancer (PCa) develop the aggressive and lethal form of the disease known as treatment-induced neuroendocrine prostate cancer (t-NEPC). Owing to lack of treatment options, the identification of the underlying molecular mechanisms that propagate the t-NEPC phenotype is critical towards developing novel therapeutic strategies against advanced PCa. Further, the roles of extracellular vesicles (exosomes) and microRNAs-an increasingly recognized and key mode of propagation of the NEPC phenotype-remain elusive. Our studies reveal that TBX2 promotes SOX2- and N-MYC- driven t-NEPC through regulation of the intermediary factor-miR-200c-3p; and that TBX2/miR-200c-3p/SOX2/MYCN signaling can promote t-NEPC via both intracellular and exosome-mediated intercellular mechanisms. Deciphering the mechanisms that drive transdifferentiation to neuroendocrine prostate cancer (NEPC) is crucial to identifying novel therapeutic strategies against this lethal and aggressive subtype of advanced prostate cancer (PCa). Further, the role played by exosomal microRNAs (miRs) in mediating signaling mechanisms that propagate the NEPC phenotype remains largely elusive. The unbiased differential miR expression profiling of human PCa cells genetically modulated for TBX2 expression led to the identification of miR-200c-3p. Our findings have unraveled the TBX2/miR-200c-3p/SOX2/N-MYC signaling axis in NEPC transdifferentiation. Mechanistically, we found that: (1) TBX2 binds to the promoter and represses the expression of miR-200c-3p, a miR reported to be lost in castrate resistant prostate cancer (CRPC), and (2) the repression of miR-200c-3p results in the increased expression of its targets SOX2 and N-MYC. In addition, the rescue of mir-200c-3p in the context of TBX2 blockade revealed that miR-200c-3p is the critical intermediary effector in TBX2 regulation of SOX2 and N-MYC. Further, our studies show that in addition to the intracellular mode, TBX2/miR-200c-3p/SOX2/N-MYC signaling can promote NEPC transdifferentiation via exosome-mediated intercellular mechanism, an increasingly recognized and key mode of propagation of the NEPC phenotype.
引用
收藏
页数:18
相关论文
共 50 条
  • [1] Urine miR-21-5p and miR-200c-3p as potential non-invasive biomarkers in patients with prostate cancer
    Danarto, Raden
    Astuti, Indwiani
    Umbas, Rainy
    Haryana, Sofia
    [J]. TURKISH JOURNAL OF UROLOGY, 2020, 46 (01): : 26 - 30
  • [2] MiR-200c-3p increased HDMEC proliferation through the notch signaling pathway
    Hu, Xianyu
    Bai, Suwen
    Li, Lingyi
    Tian, Pengfei
    Wang, Sun
    Zhang, Ning
    Shen, Bing
    Du, Juan
    Liu, Shengxiu
    [J]. EXPERIMENTAL BIOLOGY AND MEDICINE, 2021, 246 (08) : 897 - 905
  • [3] Exosome-mediated circGMPS facilitates the development of gastric cancer cells through miR-144-3p/PUM1
    Zhang, Yuexin
    Xie, Wenrui
    Zheng, Wenhong
    Qian, Xiaoying
    Deng, Chengwei
    [J]. CYTOTECHNOLOGY, 2024, 76 (01) : 53 - 68
  • [4] Exosome-mediated circGMPS facilitates the development of gastric cancer cells through miR-144-3p/PUM1
    Yuexin Zhang
    Wenrui Xie
    Wenhong Zheng
    Xiaoying Qian
    Chengwei Deng
    [J]. Cytotechnology, 2024, 76 : 53 - 68
  • [5] TBX2 promotes prostate cancer bone-metastatic phenotype through exosomal microRNA-375-3p.
    Patel, Girijesh Kumar
    Dutta, Sayanika
    Khedmatgozar, Hamed
    Tripathi, Manisha
    Nandana, Srinivas
    [J]. CANCER RESEARCH, 2022, 82 (12)
  • [6] Tissue miR-200c-3p and circulating miR-1290 as potential prognostic biomarkers for colorectal cancer
    Enoch Kang
    Sung Cheol Jung
    Soo Kyung Nam
    Yujun Park
    Soo Hyun Seo
    Kyoung Un Park
    Heung-Kwon Oh
    Duck-Woo Kim
    Sung-Bum Kang
    Hye Seung Lee
    [J]. Scientific Reports, 12
  • [7] miR-200c-3p regulates α4 integrin-mediated T cell adhesion and migration
    Mokmued, Khwanchanok
    Obeng, Gideon
    Kawamoto, Eiji
    Caidengbate, Siqingaowa
    Leangpanich, Supasuta
    Akama, Yuichi
    Gaowa, Arong
    Shimaoka, Motomu
    Park, Eun Jeong
    [J]. EXPERIMENTAL CELL RESEARCH, 2024, 440 (02)
  • [8] Tissue miR-200c-3p and circulating miR-1290 as potential prognostic biomarkers for colorectal cancer
    Kang, Enoch
    Jung, Sung Cheol
    Nam, Soo Kyung
    Park, Yujun
    Seo, Soo Hyun
    Park, Kyoung Un
    Oh, Heung-Kwon
    Kim, Duck-Woo
    Kang, Sung-Bum
    Lee, Hye Seung
    [J]. SCIENTIFIC REPORTS, 2022, 12 (01)
  • [9] Circulating miR-141-3p, miR-143-3p and miR-200c-3p are differentially expressed in colorectal cancer and advanced adenomas
    Javier Ardila, Hector
    Carolina Sanabria-Salas, Maria
    Meneses, Ximena
    Rios, Rafael
    Huertas-Salgado, Antonio
    Lucia Serrano, Martha
    [J]. MOLECULAR AND CLINICAL ONCOLOGY, 2019, 11 (02) : 201 - 207
  • [10] Downregulation of miR-200c-3p contributes to the resistance of breast cancer cells to paclitaxel by targeting SOX2
    Chen, Junqing
    Tian, Wei
    He, Haifei
    Chen, Feng
    Huang, Jian
    Wang, Xiaojia
    Chen, Zhanhong
    [J]. ONCOLOGY REPORTS, 2018, 40 (06) : 3821 - 3829